合成路线1
该中间体在本合成路线中的序号:
(XI) 2) Hexadeuteroethyl alcohol (IX) is treated with red phosphorus and I2 at reflux temperature to give pentadeuteroethyl iodide (X), which is condensed with potassium phthalimide (XI) in DMF, yielding N-(pentadeuteroethyl)phthalimide (XII). The hydrolysis of (XII) with hydrazine and HCl affords pentadeuteroethylamine (XIII), which is condensed with 1-methylpiperidin-4-one (III) and formaldehyde (XIV) in a Mannich reaction to give 3-methyl-7-(pentadeuteroethyl)-3,7-diazabicyclo[3.3.1]nonan-9-one (XV). The reduction of (XV) with NaBH4 as before yields the diastereomeric mixture (XVI + XVII). Finally, the alpha-isomer (XVI) is condensed with 4-chlorobenzoyl chloride (VIII) as before to give the pentadeuterium-labeled bisaramil.
【1】
Mlinko, S.; Simon Trompler, E.; Szammer, J.; Synthesis of bisaramil labelled with carbon-14 and deuterium. J Label Compd Radiopharm 1994, 34, 4, 313.
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(III) |
10919 |
1-Methyl-4-piperidone; 1-Methyltetrahydro-4(1H)-pyridinone; N-Methyl-4-piperidone;1-methylpiperidin-4-one |
1445-73-4 |
C6H11NO |
详情 | 详情
|
(VIII) |
10295 |
p-Chlorobenzoyl chloride; 4-Chlorobenzoyl chloride
|
122-01-0 |
C7H4Cl2O |
详情 | 详情
|
(IX) |
10924 |
Ethyl alcohol; Ethanol
|
1516-08-1 |
C2H6O |
详情 | 详情
|
(IX) |
44687 |
Ethanol-d6
|
|
C2H6O |
详情 |
详情
|
(X) |
10925 |
Iodoethane;ethyl iod |
75-03-6 |
C2H5I |
详情 | 详情
|
(X) |
44688 |
1-iodoethane-d5
|
|
C2H5I |
详情 |
详情
|
(XI) |
10926 |
(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)potassium
|
|
C8H4KNO2 |
详情 |
详情
|
(XII) |
10927 |
2-Ethyl-1H-isoindole-1,3(2H)-dione
|
5022-29-7 |
C10H9NO2 |
详情 | 详情
|
(XII) |
44689 |
2-ethyl-1H-isoindole-1,3(2H)-dione
|
|
C10H9NO2 |
详情 |
详情
|
(XIII) |
10928 |
Ethanamine
|
75-04-7 |
C2H7N |
详情 | 详情
|
(XIII) |
44690 |
ethylamine; 1-ethanamine
|
|
C2H7N |
详情 |
详情
|
(XV) |
10929 |
3-Ethyl-7-methyl-3,7-diazabicyclo[3.3.1]nonan-9-one
|
|
C10H18N2O |
详情 |
详情
|
(XV) |
44691 |
3-ethyl-7-methyl-3,7-diazabicyclo[3.3.1]nonan-9-one
|
|
C10H18N2O |
详情 |
详情
|
(XVI) |
10921 |
3-Ethyl-7-methyl-3,7-diazabicyclo[3.3.1]nonan-9-ol
|
|
C10H20N2O |
详情 |
详情
|
(XVI) |
44692 |
3-ethyl-7-methyl-3,7-diazabicyclo[3.3.1]nonan-9-ol
|
|
C10H20N2O |
详情 |
详情
|
(XVII) |
10922 |
3-Ethyl-7-methyl-3,7-diazabicyclo[3.3.1]nonan-9-ol
|
|
C10H20N2O |
详情 |
详情
|
(XVII) |
44693 |
3-ethyl-7-methyl-3,7-diazabicyclo[3.3.1]nonan-9-ol
|
|
C10H20N2O |
详情 |
详情
|
合成路线2
该中间体在本合成路线中的序号:
(III) 1) The mesylation of 5'-O-tritylthymidine with mesyl chloride gives the corresponding 3'-O-mesyl derivative (II), which is cyclized by means of potassium phthalimide (III) in hot DMF water, yielding 5'-O-trityl-2,3'-anhydrothymidine (IV). The reaction of (IV) with sodium azide in refluxing DMF - water affords 5'-O-trityl-3'-azido-3'-deoxy thymidine (V), which is finally deprotected with 80% aqueous acetic acid at 100 C.
【1】
Glinski, R.P.; et al.; Nucleotide synthesis. IV. Phosphorylated 3'-amino-3'-deoxythymidine and 5'-amino-5'-deoxythymidine and derivatives. J Org Chem 1973, 38, 25, 4299.
|
【2】
Castaner, J.; Prous, J.; BW-A 509 U. Drugs Fut 1986, 11, 12, 1017.
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
12166 |
1-[(2R,4S,5R)-4-Hydroxy-5-[(trityloxy)methyl]tetrahydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione
|
|
C29H28N2O5 |
详情 |
详情
|
(II) |
12196 |
(2R,3S,5R)-5-[5-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl]-2-[(trityloxy)methyl]tetrahydro-3-furanyl methanesulfonate
|
|
C30H30N2O7S |
详情 |
详情
|
(III) |
10926 |
(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)potassium
|
|
C8H4KNO2 |
详情 |
详情
|
(IV) |
12168 |
(1R,9R,10R)-4-Methyl-10-[(trityloxy)methyl]-8,11-dioxa-2,6-diazatricyclo[7.2.1.0(2,7)]dodeca-3,6-dien-5-one
|
|
C29H26N2O4 |
详情 |
详情
|
(V) |
24469 |
1-[4-azido-5-[(trityloxy)methyl]tetrahydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione
|
|
C29H27N5O4 |
详情 |
详情
|
合成路线3
该中间体在本合成路线中的序号:
(II) A new synthesis for Y-26611 has been reported:
The reaction of 4-benzyl-2-(chloromethyl)morpholine (I) with potassium phthalimide (II) in refluxing DMF gives 4-benzyl-2-(phthalimidomethyl)morpholine (III), which is treated with hydrazine hydrate in refluxing ethanol yielding 2-(aminomethyl)-4-benzylmorpholine (IV). The acetylation of (IV) with acetic anhydride in cool toluene affords 2-(acetamidomethyl)-4-benzylmorpholine (V), which is debenzylated by hydrogenation with hydrazine hydrate over Pd/C in isopropanol to give 2-(acetamidomethyl)morpholine (VI). The condensation of (VI) with 1-cyclopropyl-6,7,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (VII) by means of triethylamine in refluxing acetonitrile yields 7-[2-(acetamidomethyl)morpholin-4-yl]-1-cyclopropyl-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (VIII), which is finally deacetylated with refluxing aqueous HCl.
【1】
Hirayama, F.; Yokoyama, Y.; Moriguchi, A.; Ikeda, Y.; Araki, K.; Iwao, E.; Uemori, S.; Yakushiji, T.; Kuroda, T.; Quinolone antimicrobial agents substituted with morpholines at the 7-position. Syntheses and structure-activity relationships. J Med Chem 1993, 36, 10, 1356. |
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
13396 |
4-Benzyl-2-(chloromethyl)morpholine
|
|
C12H16ClNO |
详情 |
详情
|
(II) |
10926 |
(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)potassium
|
|
C8H4KNO2 |
详情 |
详情
|
(III) |
13398 |
2-[(4-Benzyl-2-morpholinyl)methyl]-1H-isoindole-1,3(2H)-dione
|
|
C20H20N2O3 |
详情 |
详情
|
(IV) |
13399 |
(4-Benzyl-2-morpholinyl)methylamine; (4-Benzyl-2-morpholinyl)methanamine
|
|
C12H18N2O |
详情 |
详情
|
(V) |
13400 |
N-[(4-Benzyl-2-morpholinyl)methyl]acetamide
|
|
C14H20N2O2 |
详情 |
详情
|
(VI) |
13401 |
N-(2-Morpholinylmethyl)acetamide
|
|
C7H14N2O2 |
详情 |
详情
|
(VII) |
13393 |
1-Cyclopropyl-6,7,8-trifluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
|
|
C13H8F3NO3 |
详情 |
详情
|
(VIII) |
13403 |
7-[2-[(Acetamido)methyl]-4-morpholinyl]-1-cyclopropyl-6,8-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
|
|
C20H21F2N3O5 |
详情 |
详情
|
合成路线4
该中间体在本合成路线中的序号:
(XII) Reaction of 1,4-dibromopentane (XI) with potassium phthalimide (XII) gives N-(4-bromopentyl)phthalimide (XIII), which is then treated with NaI in refluxing acetone.
【1】
McIntyre, J.A.; Castaner, J.; Bayes, M.; Tafenoquine Succinate. Drugs Fut 2003, 28, 9, 859.
|
【2】
Ugwuegbulam, C.O.; Foy, J.E. (GlaxoSmithKline Inc.; GlaxoSmithKline plc); Process for the preparation of anti-malarial drugs. US 6479660; WO 9713753 .
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(IX) |
48082 |
2-(4-iodopentyl)-1H-isoindole-1,3(2H)-dione
|
|
C13H14INO2 |
详情 |
详情
|
(XI) |
57248 |
1,4-dibromopentane
|
|
C5H10Br2 |
详情 |
详情
|
(XII) |
10926 |
(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)potassium
|
|
C8H4KNO2 |
详情 |
详情
|
(XIII) |
57249 |
2-(4-bromopentyl)-1H-isoindole-1,3(2H)-dione
|
|
C13H14BrNO2 |
详情 |
详情
|
合成路线5
该中间体在本合成路线中的序号:
(VII) The starting compound phthalimido derivative (I) could be obtained as follows:
The condensation of 2-[2-(2-chloroethoxy)ethoxy]ethanol (VI) with potassium phthalimide (VII) in refluxing DMF gives the expected phthalimido derivative (VIII), which is oxidized with the Jones reagent in acetone yielding 2-[2-(2-phthalimidoethoxy)ethoxy]acetic acid (IX). The condensation of (IX) with 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum's acid) (X) by means of carbonyldiimidazole (CDI) and pyridine in dichloromethane affords 2,2-dimethyl-5-[2-[2-(2-phthalimidoethoxy)ethoxy]acetyl]-1,3-dioxane-4,6-dione (XI), which is finally treated with refluxing ethanol to obtain the phthalimido derivative (I) used as starting material.
【1】
Crouzel, C.; Duval, R.; Hinnen, F.; Fuseau, C.; Dollé, F.; Valette, H.; Péglion, J.-L.; Synthesis of two optically active calcium channel antagonists labelled with carbon-11 for in vivo cardiac PET imaging. Bioorg Med Chem 1997, 5, 4, 749. |
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
14743 |
ethyl 4-[2-[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]ethoxy]-3-oxobutanoate
|
|
C18H21NO7 |
详情 |
详情
|
(VI) |
14748 |
2-[2-(2-Chloroethoxy)ethoxy]-1-ethanol; 2-(2-(2-Chloroethoxy)ethoxy)ethanol
|
5197-62-6 |
C6H13ClO3 |
详情 | 详情
|
(VII) |
10926 |
(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)potassium
|
|
C8H4KNO2 |
详情 |
详情
|
(VIII) |
14750 |
2-[2-[2-(2-Hydroxyethoxy)ethoxy]ethyl]-1H-isoindole-1,3(2H)-dione
|
|
C14H17NO5 |
详情 |
详情
|
(IX) |
14751 |
2-[2-[2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)ethoxy]ethoxy]acetic acid
|
|
C14H15NO6 |
详情 |
详情
|
(X) |
14738 |
Meldrum's acid; 2,2-dimethyl-1,3-dioxane-4,6-dione;Malonic acid cyclic isopropylidene ester |
2033-24-1 |
C6H8O4 |
详情 | 详情
|
(XI) |
14752 |
2-(2-[2-[2-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-2-oxoethoxy]ethoxy]ethyl)-1H-isoindole-1,3(2H)-dione
|
|
C20H21NO9 |
详情 |
详情
|
合成路线6
该中间体在本合成路线中的序号:
(II) Substitution on dibromobutene (I) by potassium phthalimide (II) provided bromobutenyl phthalimide (III). Further treatment with sodium acetate afforded acetate (IV) which, after hydrolysis, gave phthalimidobutenol (V). Reaction with refluxing ethyl orthoacetate in the presence of a trace of butyric acid generated the intermediate ketene acetal (VI), which experienced a Claisen rearrangement to give pentenoate ester (VII). Ozonolysis of the olefinic double bond of (VII) yielded aldehyde (VIII). Then, Wittig reaction of aldehyde (VIII) with (isopropylidene)triphenylphosphorane in cold THF provided olefin (IX), which was hydrogenated in the presence of Pd/C to give the isobutyl compound (X). Finally, hydrolysis of both ester and phthalimide groups in refluxing 6 N HCl provided the GABA analogue.
【1】
Serfass, L.; Casara, P.J.; General synthesis of 3-substituted alkenyl GABA as potential anticonvulsants. Bioorg Med Chem Lett 1998, 8, 18, 2599.
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
18349 |
(E)-1,4-dibromo-2-butene;trans-1,4-dibromo-2-butene |
821-06-7 |
C4H6Br2 |
详情 | 详情
|
(II) |
10926 |
(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)potassium
|
|
C8H4KNO2 |
详情 |
详情
|
(III) |
18351 |
2-[(E)-4-bromo-2-butenyl]-1H-isoindole-1,3(2H)-dione
|
|
C12H10BrNO2 |
详情 |
详情
|
(IV) |
18352 |
(E)-4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-butenyl acetate
|
|
C14H13NO4 |
详情 |
详情
|
(V) |
18353 |
2-[(E)-4-hydroxy-2-butenyl]-1H-isoindole-1,3(2H)-dione
|
|
C12H11NO3 |
详情 |
详情
|
(VI) |
18354 |
2-[(E)-4-[(1-ethoxyvinyl)oxy]-2-butenyl]-1H-isoindole-1,3(2H)-dione
|
|
C16H17NO4 |
详情 |
详情
|
(VII) |
18355 |
ethyl 3-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-4-pentenoate
|
|
C16H17NO4 |
详情 |
详情
|
(VIII) |
18356 |
ethyl 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-formylbutanoate
|
|
C15H15NO5 |
详情 |
详情
|
(IX) |
18357 |
ethyl 3-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-methyl-4-hexenoate
|
|
C18H21NO4 |
详情 |
详情
|
(X) |
18358 |
ethyl 3-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-5-methylhexanoate
|
|
C18H23NO4 |
详情 |
详情
|
合成路线7
该中间体在本合成路线中的序号:
(VIII) A new synthesis of S-4661 has been reported:
The esterification of trans-4-hydroxy-L-proline (I) with methanol/HCl gives the corresponding methyl ester (II), which is N-protected as trans-N-(4-methoxybenzyloxycarbonyl)-4-hydroxy-L-proline methyl ester (III). The mesylation of (III) with methanesulfonyl chloride and triethylamine in dichloromethane affords the 4-O-mesylate (IV), which is treated with sodium triphenylmethylsulfide giving cis-N-(4-methoxybenzyloxycarbonyl)-4-(triphenylmethylsulfanyl)-L-prolin e methyl ester (V). The reduction of (V) with LiBH4 in THF yields the corresponding methanol (VI), which is mesylated as before affording (VII). The reaction of (VII) with potassium phthalimide (VIII) gives the adduct (IX), which is cleaved with hydrazine yielding (2S,4S)-2-(aminomethyl)-1-(4-methoxybenzyloxycarbonyl)-4-(triphenylmeth ylsulfanyl)pyrrolidine (X). The condensation of (X) with N-(4-methoxybenzyl)sulfamoyl chloride (XI) by means of triethylamine affords the corresponding protected sulfamide (XII). Deprotection of the trityl group of (XII) by treatment with silver nitrate and pyridine affords compound (XIII) with a free SH group. The reaction of (XIII) with (1R,5S,6S)-2-(diphenoxyphosphoryloxy)-6-[1(R)-hydroxyethyl]-1-methyl-1-carba-2-penem-3-carboxylic acid 4-methoxybenzyl ester (XIV) by means of diisopropylethylamine yields the protected final product (XV), which is finally treated with AlCl3 in anisole to eliminate the protecting groups.
【1】
Iso, Y.; Motokawa, K.; Nishitani, Y.; Nishino, Y.; Irie, T.; A novel 1beta-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1beta-methylcarbapenems. J Antibiot 1996, 49, 2, 199. |
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
14489 |
(2S,4R)-4-hydroxytetrahydro-1H-pyrrole-2-carboxylic acid; L-Hydroxyproline
|
51-35-4 |
C5H9NO3 |
详情 | 详情
|
(II) |
15796 |
methyl (2S,4R)-4-hydroxytetrahydro-1H-pyrrole-2-carboxylate
|
|
C6H11NO3 |
详情 |
详情
|
(III) |
16080 |
1-(4-methoxybenzyl) 2-methyl (2S,4R)-4-hydroxytetrahydro-1H-pyrrole-1,2-dicarboxylate
|
|
C15H19NO6 |
详情 |
详情
|
(IV) |
16081 |
1-(4-methoxybenzyl) 2-methyl (2S,4R)-4-[(methylsulfonyl)oxy]tetrahydro-1H-pyrrole-1,2-dicarboxylate
|
|
C16H21NO8S |
详情 |
详情
|
(V) |
16082 |
1-(4-methoxybenzyl) 2-methyl (2S,4S)-4-(tritylsulfanyl)-1,2-pyrrolidinedicarboxylate
|
|
C34H33NO5S |
详情 |
详情
|
(VI) |
16083 |
4-methoxybenzyl (2S,4S)-2-(hydroxymethyl)-4-(tritylsulfanyl)-1-pyrrolidinecarboxylate
|
|
C33H33NO4S |
详情 |
详情
|
(VII) |
16084 |
4-methoxybenzyl (2S,4S)-2-[[(methylsulfonyl)oxy]methyl]-4-(tritylsulfanyl)-1-pyrrolidinecarboxylate
|
|
C34H35NO6S2 |
详情 |
详情
|
(VIII) |
10926 |
(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)potassium
|
|
C8H4KNO2 |
详情 |
详情
|
(IX) |
16086 |
4-methoxybenzyl (2S,4S)-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-4-(tritylsulfanyl)-1-pyrrolidinecarboxylate
|
|
C41H36N2O5S |
详情 |
详情
|
(X) |
16087 |
4-methoxybenzyl (2S,4S)-2-(aminomethyl)-4-(tritylsulfanyl)-1-pyrrolidinecarboxylate
|
|
C33H34N2O3S |
详情 |
详情
|
(XI) |
16088 |
chloro([[(4-methoxybenzyl)oxy]carbonyl]amino)dioxo-lambda(6)-sulfane
|
|
C9H10ClNO5S |
详情 |
详情
|
(XII) |
16089 |
4-methoxybenzyl (2S,4S)-2-([[([[(4-methoxybenzyl)oxy]carbonyl]amino)sulfonyl]amino]methyl)-4-(tritylsulfanyl)-1-pyrrolidinecarboxylate
|
|
C42H43N3O8S2 |
详情 |
详情
|
(XIII) |
16090 |
4-methoxybenzyl (2S,4S)-2-([[([[(4-methoxybenzyl)oxy]carbonyl]amino)sulfonyl]amino]methyl)-4-sulfanyl-1-pyrrolidinecarboxylate
|
|
C23H29N3O8S2 |
详情 |
详情
|
(XIV) |
16075 |
4-methoxybenzyl (4R,5R,6S)-3-[(diphenoxyphosphoryl)oxy]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
|
|
C30H30NO9P |
详情 |
详情
|
(XV) |
16092 |
4-methoxybenzyl (4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-3-[[(3S,5S)-1-[[(4-methoxybenzyl)oxy]carbonyl]-5-([[([[(4-methoxybenzyl)oxy]carbonyl]amino)sulfonyl]amino]methyl)pyrrolidinyl]sulfanyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
|
|
C41H48N4O13S2 |
详情 |
详情
|
合成路线8
该中间体在本合成路线中的序号:
(VIII) 2) The chiral intermediates the amine (I) and the acid (II) have been obtained as follows: 2a) The bromination of 1-tetralone (IV) with Br2 in methanol gives the 2-bromotetralone (V), which is treated with hydroxylamine yielding the corresponding oximae (VI). The isomerization of (V) with polyphosphoric acid (PPA) at 80 C affords the benzazepinone (VII), which is treated with potassium phthalimide (VIII) in DMF to give the corresponding phthalimido derivative (IX). The reaction of (IX) with tert-butyl bromoacetate (X) by means of potassium tert-butoxide in DMF yields the benzazepinoacetic ester (XI), which is treated with hot ethanolamine to eliminate the phthalimido group yielding racemic (I). Finally, this racemate is submitted to optical resolution with L-(+)-tartaric acid to afford the chiral (S)-intermediate (I).
【1】
Waldeck, H.; Höltje, D.; Messinger, J.; Antel, J.; Wurl, M.; Thormählen, D. (Kali-Chemie AG); Benzazepin-, benzoxazepin- and benzothiazepin-N-acetic acid-derivs., their preparation and their pharmaceutical compsns.. CA 2172354; EP 0733642; JP 1996269011; US 5677297 . |
【2】
Rozsa, S.; Gy Papp, J.; Thormahlen, D.; Waldeck, H. (Solvay SA); Drugs for increasing gastrointestinal blood supply. DE 19638020; EP 0830863; JP 1998101565 .
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
rac-(I) |
20728 |
tert-butyl 2-(3-amino-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)acetate
|
|
C16H22N2O3 |
详情 |
详情
|
(I) |
20717 |
tert-butyl 2-[(3S)-3-amino-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetate
|
|
C16H22N2O3 |
详情 |
详情
|
(IV) |
20720 |
3,4-dihydro-1(2H)-naphthalenone
|
529-34-0 |
C10H10O |
详情 | 详情
|
(V) |
20721 |
2-bromo-3,4-dihydro-1(2H)-naphthalenone
|
|
C10H9BrO |
详情 |
详情
|
(VI) |
20722 |
2-bromo-3,4-dihydro-1(2H)-naphthalenone oxime
|
|
C10H10BrNO |
详情 |
详情
|
(VII) |
20723 |
3-bromo-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one
|
|
C10H10BrNO |
详情 |
详情
|
(VIII) |
10926 |
(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)potassium
|
|
C8H4KNO2 |
详情 |
详情
|
(IX) |
20725 |
2-(2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl)-1H-isoindole-1,3(2H)-dione
|
|
C18H14N2O3 |
详情 |
详情
|
(X) |
17430 |
2-Bromoacetic acid tert-butyl ester; tert-butyl 2-bromoacetate; tert-Butyl bromoacetate
|
5292-43-3 |
C6H11BrO2 |
详情 | 详情
|
(XI) |
20727 |
tert-butyl 2-[3-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetate
|
|
C25H26N2O5 |
详情 |
详情
|
合成路线9
该中间体在本合成路线中的序号:
(VIII) 2a) The chiral intermediate amine (I) has been obtained as follows:
The bromination of 1-tetralone (IV) with Br2 in methanol gives the 2-bromotetralone (V), which is treated with hydroxylamine yielding the corresponding oximae (VI). The isomerization of (V) with polyphosphoric acid (PPA) at 80 C affords the benzazepinone (VII), which is treated with potassium phthalimide (VIII) in DMF to give the corresponding phthalimido derivative (IX). The reaction of (IX) with tert-butyl bromoacetate (X) by means of potassium tert-butoxide in DMF yields the benzazepinoacetic ester (XI), which is treated with hot ethanolamine to eliminate the phthalimido group yielding racemic (I). Finally, this racemate is submitted to optical resolution with L-(+)-tartaric acid to afford the chiral (S)-intermediate (I).
【1】
Sorbera, L.A.; Leeson, P.A.; Castañer, J.; SLV-306. Drugs Fut 2002, 27, 1, 27.
|
【2】
Waldeck, H.; Höltje, D.; Messinger, J.; Antel, J.; Wurl, M.; Thormählen, D. (Kali-Chemie AG); Benzazepin-, benzoxazepin- and benzothiazepin-N-acetic acid-derivs., their preparation and their pharmaceutical compsns.. CA 2172354; EP 0733642; JP 1996269011; US 5677297 . |
【3】
Rozsa, S.; Gy Papp, J.; Thormahlen, D.; Waldeck, H. (Solvay SA); Drugs for increasing gastrointestinal blood supply. DE 19638020; EP 0830863; JP 1998101565 .
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
rac-(I) |
20728 |
tert-butyl 2-(3-amino-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)acetate
|
|
C16H22N2O3 |
详情 |
详情
|
(I) |
20717 |
tert-butyl 2-[(3S)-3-amino-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetate
|
|
C16H22N2O3 |
详情 |
详情
|
(IV) |
20720 |
3,4-dihydro-1(2H)-naphthalenone
|
529-34-0 |
C10H10O |
详情 | 详情
|
(V) |
20721 |
2-bromo-3,4-dihydro-1(2H)-naphthalenone
|
|
C10H9BrO |
详情 |
详情
|
(VI) |
20722 |
2-bromo-3,4-dihydro-1(2H)-naphthalenone oxime
|
|
C10H10BrNO |
详情 |
详情
|
(VII) |
20723 |
3-bromo-1,3,4,5-tetrahydro-2H-1-benzazepin-2-one
|
|
C10H10BrNO |
详情 |
详情
|
(VIII) |
10926 |
(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)potassium
|
|
C8H4KNO2 |
详情 |
详情
|
(IX) |
20725 |
2-(2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl)-1H-isoindole-1,3(2H)-dione
|
|
C18H14N2O3 |
详情 |
详情
|
(X) |
17430 |
2-Bromoacetic acid tert-butyl ester; tert-butyl 2-bromoacetate; tert-Butyl bromoacetate
|
5292-43-3 |
C6H11BrO2 |
详情 | 详情
|
(XI) |
20727 |
tert-butyl 2-[3-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetate
|
|
C25H26N2O5 |
详情 |
详情
|
合成路线10
该中间体在本合成路线中的序号:
(I) Alkylation of potassium phthalimide (I) with an excess of 1,8-dibromooctane (II) in refluxing acetone afforded N-(8-bromooctyl)phthalimide (III). This was condensed with 6-O-demethylgalanthamine (IV) in the presence of Et3N in boiling acetonitrile to give phthalimidooctyl compound (V). Finally, reaction with N-bromosuccinimide in the presence of azobisisobutyronitrile provided the iminium bromide.
【1】
Mary, A.; Renko, D.Z.; Guillou, C.; Thal, C.; Potent acetylcholinesterase inhibitors: Design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series. Bioorg Med Chem 1998, 6, 10, 1835.
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
10926 |
(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)potassium
|
|
C8H4KNO2 |
详情 |
详情
|
(II) |
18610 |
1,8-dibromooctane
|
4549-32-0 |
C8H16Br2 |
详情 | 详情
|
(III) |
18611 |
2-(8-bromooctyl)-1H-isoindole-1,3(2H)-dione
|
17702-83-9 |
C16H20BrNO2 |
详情 | 详情
|
(IV) |
18612 |
(6R,8aS)-3-methoxy-5,6,9,10,11,12-hexahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-6-ol
|
|
C16H19NO3 |
详情 |
详情
|
(V) |
18613 |
2-[8-[(6R,8aS)-6-hydroxy-3-methoxy-5,6,9,10-tetrahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-11(12H)-yl]octyl]-1H-isoindole-1,3(2H)-dione
|
|
C32H38N2O5 |
详情 |
详情
|
合成路线11
该中间体在本合成路线中的序号:
(XIV) After bromination of the methyl group of (XII) with N-bromosuccinimide in the presence of 2,2'-azobis(isobutyro-nitrile) to give (XIII), the aminomethyl derivative (XVI) was obtained by condensation with potassium phthalimide (XIV) in DMF and subsequent hydrazinolysis of the resulting (XV). Treatment with methanesulfonyl chloride and triethylamine then provided sulfonamide (XVII), and the ester function was finally hydrolyzed to the target carboxylic acid with NaOH in a mixture of H2O/MeOH/THF.
【1】
Cho, N.; Nara, Y.; Harada, M.; Sugo, T.; Masuda, Y.; Abe, A.; Kusumoto, K.; Itoh, Y.; Ohtaki, T.; Watanabe, T.; Furuya, S.; Thieno[2,3-d]pyrimidine-3-acetic acids a new class of nonpeptide endothelin receptor antagonists. Chem Pharm Bull 1998, 46, 11, 1724. |
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(XII) |
18320 |
ethyl 2-[6-[4-(methoxymethoxy)phenyl]-5-methyl-1-[2-(methylsulfanyl)benzyl]-2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl]acetate
|
|
C27H28N2O6S2 |
详情 |
详情
|
(XIII) |
18321 |
ethyl 2-[5-(bromomethyl)-6-[4-(methoxymethoxy)phenyl]-1-[2-(methylsulfanyl)benzyl]-2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl]acetate
|
|
C27H27BrN2O6S2 |
详情 |
详情
|
(XIV) |
10926 |
(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)potassium
|
|
C8H4KNO2 |
详情 |
详情
|
(XV) |
18323 |
ethyl 2-[5-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]-6-[4-(methoxymethoxy)phenyl]-1-[2-(methylsulfanyl)benzyl]-2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl]acetate
|
|
C35H31N3O8S2 |
详情 |
详情
|
(XVI) |
18324 |
ethyl 2-[5-(aminomethyl)-6-[4-(methoxymethoxy)phenyl]-1-[2-(methylsulfanyl)benzyl]-2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl]acetate
|
|
C27H29N3O6S2 |
详情 |
详情
|
(XVII) |
18325 |
ethyl 2-[6-[4-(methoxymethoxy)phenyl]-1-[2-(methylsulfanyl)benzyl]-5-[[(methylsulfonyl)amino]methyl]-2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidin-3(2H)-yl]acetate
|
|
C28H31N3O8S3 |
详情 |
详情
|
合成路线12
该中间体在本合成路线中的序号:
(IV) Condensation of epichlorohydrin (I) with N-benzylethanolamine (II) in the presence of sulfuric acid afforded the (chloromethyl)morpholine (III). Halogen displacement in (III) by potassium phthalimide (IV) provided the substituted phthalimide (V). Further hydrazinolysis of (V) furnished racemic (aminomethyl)morpholine (VI) (1). The desired (S) enantiomer (VII) was obtained by crystallization of (VI) as the dibenzoyl-D-tartaric acid salt, followed by liberation of the base with NaOH. Eschweiler-Clarke reductive methylation of (VII) with formaldehyde and formic acid produced the dimethylamino derivative (VIII). The N-benzyl groupof (VIII) was then cleaved by transfer hydrogenation in the presence of hydrazine and Pd/C yielding chiral morpholine (IX). Finally, coupling of this morpholine (IX) with the difluoroqyuinolone boron chelate (X) provided the title morpholino quinolone.
【1】
Sakurai, N.; Sano, M.; Hirayama, F.; Kuroda, T.; Uemori, S.; Moriguchi, A.; Yamamoto, K.; Ikeda, Y.; Kawakita, T.; Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents. Bioorg Med Chem Lett 1998, 8, 16, 2185. |
【2】
Uemori, S.; Hirayama, F.; Moriguchi, A.; Sano, M.; Yokoyama, Y.; Ikeda, Y.; Miyoshi, M.; Sakurai, N.; Yamamoto, K.; Kawakita, T.; Synthesis and anti-Helicobacter pylori activity of Y-34867, a new 7-morpholinoquinolone. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24 1998, San Diego) 1998, Abst F-85. |
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
10146 |
Epichlorohydrin; 2-(Chloromethyl)oxirane
|
106-89-8 |
C3H5ClO |
详情 | 详情
|
(II) |
25630 |
2-(benzylamino)-1-ethanol
|
104-63-2 |
C9H13NO |
详情 | 详情
|
(III) |
13396 |
4-Benzyl-2-(chloromethyl)morpholine
|
|
C12H16ClNO |
详情 |
详情
|
(IV) |
10926 |
(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)potassium
|
|
C8H4KNO2 |
详情 |
详情
|
(V) |
13398 |
2-[(4-Benzyl-2-morpholinyl)methyl]-1H-isoindole-1,3(2H)-dione
|
|
C20H20N2O3 |
详情 |
详情
|
(VI) |
13399 |
(4-Benzyl-2-morpholinyl)methylamine; (4-Benzyl-2-morpholinyl)methanamine
|
|
C12H18N2O |
详情 |
详情
|
(VII) |
25362 |
1,4,8,11-Tetraazacyclotetradecane
|
295-37-4 |
C10H24N4 |
详情 | 详情
|
(VIII) |
25633 |
N-[[(2S)-4-benzylmorpholinyl]methyl]-N,N-dimethylamine
|
|
C14H22N2O |
详情 |
详情
|
(IX) |
25634 |
N,N-dimethyl-N-[(2R)morpholinylmethyl]amine
|
|
C7H16N2O |
详情 |
详情
|
(X) |
25635 |
1-Cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid diacetoxyboron complex
|
|
C18H16BF2NO8 |
详情 |
详情
|
合成路线13
该中间体在本合成路线中的序号:
(IV) Lithiation of 1-(N-N-dimethylsulfamoyl)imidazole (I) followed by reaction with tert-butyldimethylsilyl chloride produced the 2-silyl protected imidazole (II). Further lithiation of (II) allowed the introduction of a bromohexyl group at position 5 upon treatment with 1,6-dibromohexane yielding (III). Bromide (III) was subsequently converted into primary amine (VI) through a Gabriel synthesis involving condensation with potassium phthalimide (IV) with concomitant desilylation, and then hydrazinolysis of the resulting alkylated phthalimide (V). Condensation of amine (VI) with naphthalene-2-sulfonyl chloride (VII) furnished sulfonamide (VIII). The sulfamoyl protecting group of (VIII) was finally removed by hydrolysis with HCl.
【1】
Tozer, M.J.; Kalindjian, B.; Pether, M.J.; Watt, G.F.; Shankley, N.P.; Harper, E.A.; From histamine to imidazolylalkyl-sulfonamides: The design of a novel series of histamine H3-receptor antagonists. Bioorg Med Chem Lett 1999, 9, 13, 1825.
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
|
24786 |
1,6-dibromohexane
|
629-03-8 |
C6H12Br2 |
详情 | 详情
|
(I) |
11036 |
N,N-Dimethyl-1H-imidazole-1-sulfonamide
|
78162-58-0 |
C5H9N3O2S |
详情 | 详情
|
(II) |
11037 |
2-[tert-Butyl(dimethyl)silyl]-N,N-dimethyl-1H-imidazole-1-sulfonamide
|
|
C11H23N3O2SSi |
详情 |
详情
|
(III) |
27986 |
5-(6-bromohexyl)-2-[tert-butyl(dimethyl)silyl]-N,N-dimethyl-1H-imidazole-1-sulfonamide
|
|
C17H34BrN3O2SSi |
详情 |
详情
|
(IV) |
10926 |
(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)potassium
|
|
C8H4KNO2 |
详情 |
详情
|
(V) |
27987 |
5-[6-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)hexyl]-N,N-dimethyl-1H-imidazole-1-sulfonamide
|
|
C19H24N4O4S |
详情 |
详情
|
(VI) |
27988 |
5-(6-aminohexyl)-N,N-dimethyl-1H-imidazole-1-sulfonamide
|
|
C11H22N4O2S |
详情 |
详情
|
(VII) |
27989 |
2-naphthalenesulfonyl chloride
|
93-11-8 |
C10H7ClO2S |
详情 | 详情
|
(VIII) |
27990 |
N,N-dimethyl-5-[6-[(2-naphthylsulfonyl)amino]hexyl]-1H-imidazole-1-sulfonamide
|
|
C21H28N4O4S2 |
详情 |
详情
|
合成路线14
该中间体在本合成路线中的序号:
(VII)
【1】
Kawahan H, Mori M, etal.2002. Preparation of 6-aminomethyl-6,11-dihydro-5H-dibenzo[b.e]azepine as intermediate for epinastine, hydrochloride,antiallergyagent. JP 2002308851 |
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
62393 |
2-benzylaniline; 2-benzylphenylamine
|
28059-64-5 |
C13H13N |
详情 | 详情
|
(II) |
66338 |
2-benzyl-N-(3-chloroprop-1-en-2-yl)aniline |
|
C16H16ClN |
详情 | 详情
|
(III) |
62395 |
6-(chloromethyl)-11H-dibenzo[b,e]azepine
|
21535-44-4 |
C15H12ClN |
详情 | 详情
|
(IV) |
66339 |
2-((11H-dibenzo[b,e]azepin-6-yl)methyl)isoindoline-1,3-dione |
|
C23H16N2O2 |
详情 | 详情
|
(V) |
66340 |
6-(Phthalimidomethyl)-6,11-dihydro-5H-dibenz[b,e]azepine |
143878-20-0 |
C23H18N2O2 |
详情 | 详情
|
(VI) |
12465 |
6,11-Dihydro-5H-dibenzo[b,e]azepin-6-ylmethylamine; 6,11-Dihydro-5H-dibenzo[b,e]azepin-6-ylmethanamine
|
|
C15H16N2 |
详情 |
详情
|
(VII) |
10926 |
(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)potassium
|
|
C8H4KNO2 |
详情 |
详情
|
合成路线15
该中间体在本合成路线中的序号:
(IV)
【1】
Krishna Reddy P. 2005.A novel process for the preparation of linezolicl and related compounds. 2005099353[本专利为Symed Laboratories Ltd (IN)所有] |
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(IV) |
10926 |
(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)potassium
|
|
C8H4KNO2 |
详情 |
详情
|
(V) |
66499 |
(S)-2-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)isoindoline-1,3-dione |
|
C22H20FN3O5 |
详情 | 详情
|
(I) |
17015 |
3-fluoro-4-morpholinophenylamine; 3-fluoro-4-morpholinoaniline; 3-fluoro-4-(4-morpholinyl)phenylamine; 3-Fluoro-4-(4-morpholinyl)benzeneamine
|
93246-53-8 |
C10H13FN2O |
详情 | 详情
|
(II) |
66497 |
(S)-1-chloro-3-((3-fluoro-4-morpholinophenyl)amino)propan-2-ol |
|
C13H18ClFN2O2 |
详情 | 详情
|
(III) |
66498 |
(S)-5-(chloromethyl)-3-(3-fluoro-4-morpholinophenyl)oxazolidin-2-one |
|
C14H16ClFN2O3 |
详情 | 详情
|
合成路线16
该中间体在本合成路线中的序号:
(II)
【1】
Mohan Rao D.2006. Novel intermediates for linezolid and related compounds. W0 20066008754[本专利为Symed Laboratories Ltd (IN)所有] |
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(III) |
66501 |
(S)-2-(3-((3-fluoro-4-morpholinophenyl)amino)-2-hydroxypropyl)isoindoline-1,3-dione |
|
C21H22FN3O4 |
详情 | 详情
|
(V) |
66502 |
(S)-2-(oxiran-2-ylmethyl)isoindoline-1,3-dione |
|
C11H9NO3 |
详情 | 详情
|
(I) |
66497 |
(S)-1-chloro-3-((3-fluoro-4-morpholinophenyl)amino)propan-2-ol |
|
C13H18ClFN2O2 |
详情 | 详情
|
(II) |
10926 |
(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)potassium
|
|
C8H4KNO2 |
详情 |
详情
|
(IV) |
17015 |
3-fluoro-4-morpholinophenylamine; 3-fluoro-4-morpholinoaniline; 3-fluoro-4-(4-morpholinyl)phenylamine; 3-Fluoro-4-(4-morpholinyl)benzeneamine
|
93246-53-8 |
C10H13FN2O |
详情 | 详情
|
(VII) |
17021 |
(5S)-5-(aminomethyl)-3-(3-fluoro-4-morpholinophenyl)-1,3-oxazolan-2-one
|
|
C14H18FN3O3 |
详情 |
详情
|